Advertisement

 

 

The revival of an "old" marker: CD4/CD8 ratio.

The revival of an "old" marker: CD4/CD8 ratio.
Author Information (click to view)

Bruno G, Saracino A, Monno L, Angarano G,


Bruno G, Saracino A, Monno L, Angarano G, (click to view)

Bruno G, Saracino A, Monno L, Angarano G,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

AIDS reviews 2017 02 0919(2)

Abstract

The effectiveness of modern antiretroviral therapies (ART) transformed HIV infection into a chronic disease characterized by a persistent condition of inflammation and immune activation. For this reason, even thought AIDS-related mortality has been reduced with an increased life expectancy, patients living with HIV infection are more likely to develop non-AIDS events despite the achievement of a complete suppression of HIV replication. Hence, the scientific community feels the need to find new biomarkers which would be suitable in clinical practice for identifying patients who require a close monitoring because of an increased risk of developing comorbidities. A renewed interest has emerged about the usefulness of CD4/CD8 ratio as a strong marker of immune activation and immune senescence. Recently, many studies have underlined that CD4/CD8 ratio might represent a good predictor of AIDS and non-AIDS events. Herein, the potential role of the CD4/CD8 ratio for the monitoring of HIV patients in different clinical settings is reviewed.

Submit a Comment

Your email address will not be published. Required fields are marked *

three × 3 =

[ HIDE/SHOW ]